May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Growth of Small Choroidal Melanocytic Lesions
Author Affiliations & Notes
  • A.A. Mokashi
    Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Academic Unit of Ophthalmology and Orthoptics, University of Sheffield, Sheffield, United Kingdom
  • A.D. Singh
    Department of Ophthalmic Oncology, Cole Eye Institue, Cleveland Clinic Foundation, Cleveland, OH
  • J.F. Bena
    Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, OH
  • R. Jacques
    Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom
  • P.A. Rundle
    Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom
  • I.G. Rennie
    Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom
    Academic Unit of Ophthalmology and Orthoptics, University of Sheffield, Sheffield, United Kingdom
  • Footnotes
    Commercial Relationships  A.A. Mokashi, None; A.D. Singh, None; J.F. Bena, None; R. Jacques, None; P.A. Rundle, None; I.G. Rennie, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3393. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.A. Mokashi, A.D. Singh, J.F. Bena, R. Jacques, P.A. Rundle, I.G. Rennie; Growth of Small Choroidal Melanocytic Lesions . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3393.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Abstract:
 

To evaluate diagnostic factors that may predict growth of small choroidal melanocytic lesions (SCML).

 

A cohort of 240 patients with a presumptive diagnosis of SCML was followed prospectively to document growth prior to treatment. Data regarding size, location, diagnostic features, and growth were collected. To evaluate the association between potential risk factors and growth, Barnard’s exact test and Fisher’s exact test were performed for categorical variables and the Wilcoxon Rank Sum test was used for continuous factors.

 

11 SCML (4.6%) demonstrated growth within 1500 days of follow up. Patients with growth had significantly larger thickness and were significantly closer to the foveola. Significant associations with growth status were observed for gender, symptom, presence of orange pigment, and intrinsic vessels seen with ICG angiogram (Table).

 

Patients with SCML that demonstrate high risk factors should be followed closely for the initial 4 years as they are likely to represent small melanoma.

 

 

 
Keywords: oncology • melanoma • choroid 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×